Repligen Corp (RGEN) Stock Analysis
P/E 209.13×· 5Y range 0.04–210.19×· top 0% of history
Sector: Healthcare · Industry: Biological Products, (No Diagnostic Substances)
AnalystsStrong Buy28 analystsStrengths
- ✓Piotroski F-Score 7/9 — high earnings quality
- ✓Altman Z 8.5 — safe-zone balance sheet
- ✓Revenue CAGR 19.2% — durable top-line growth
- ✓Interest coverage 13.3× — debt well covered
Risks
- ⚠P/E 209.1× at top 0% of 5-year history
What's happening with RGEN
Price History
5-Year Weekly Candlestick Chart
Profile
Strong financial health and earnings quality; valuation and profitability lag behind.
How is each axis scored?
- Valuation10/100 · Weak
- P/E vs own history (100th pct)0/25
- FCF yield (1.0%)5/25
- P/S (14.0x)5/25
- EV/EBIT (162.1x)0/25
- Growth70/100 · Moderate
- Revenue CAGR (19.2%)20/25
- Net income CAGR (-5.0%)0/25
- EPS CAGR 5Y (428.0%)25/25
- Fwd implied growth (177.8%)25/25
- Profitability35/100 · Weak
- ROIC (2.7%)5/25
- ROE (2.4%)5/25
- Net margin (6.7%)13/25
- Operating margin (8.5%)12/25
- Financial Health100/100 · Strong
- Altman Z (8.54)25/25
- Current ratio (9.20)25/25
- Interest coverage (13.3x)25/25
- Net cash / debt (Net cash)25/25
- Quality84/100 · Strong
- Piotroski F (7/9)22/25
- Beneish M (-2.50)25/25
- FCF conversion (206%)25/25
- Margin stability (σ 8.3%)12/25
About Repligen Corp
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Show more
Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Headquarters: WALTHAM, MA · Employees: 2,000 · Website ↗
Insider Transactions
Recent SEC Form 4 filings
- SellOption exercise · filed 2026-09-22-5426 sh2026-09-21
- SellOpen market sale · filed 2026-09-22-5426 sh2026-09-21
- BuyOption exercise · filed 2026-09-22+5.4K sh2026-09-21
- SellOpen market sale · filed 2026-09-08-3035 sh2026-09-04
- SellTax withholding · filed 2026-09-08-2842 sh2026-09-03
+3 more recent filings
Key Metrics
Financial snapshot — pillar inputs plus per-share and market context
Valuation
10EP/E (TTM)209.1xD
Grade D: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 0.0x–210.2x · highest in history
P/FCF96.2xD
Grade D: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield1.0%C
Grade C: LowTTM FCF / Market Cap — vs own 5Y history: 0.2%–2431.0% · 10th pct
P/S (TTM)14.02xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 0.0x–34.3x · 90th pct
EV/EBIT162.1xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: -274.7x–163.7x · highest in history
EV/Sales13.4xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E75.3xD
Grade D: ExpensivePrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio5.08xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio11.27D
Grade D: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
35DROIC2.7%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE2.4%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA1.4%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin6.7%C
Grade C: AverageNet Income / Revenue
Operating Margin8.5%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin52.9%A
Grade A: PremiumGross Profit / Revenue
FCF Margin13.9%C
Grade C: AverageFCF / Revenue
True FCF Margin9.5%C
Grade C: AverageTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Financial Health
100A+Altman Z-Score8.54A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio9.20xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio7.02xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage13.3xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBITNet CashA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.26xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt1.44xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Growth
70B+Revenue CAGR19.2%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-5.0%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)428.0%A
Grade A: HighCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth177.8%A
Grade A: HighImplied 1Y EPS growth from forward P/E vs our TTM EPS. Sparse — only where forward estimates exist
Dilution (5Y)-0.4%B
Grade B: FlatShare count change over 5Y
SBC / Net Income65.5%D
Grade D: HighStock-based comp/Net income. >30% = dilution risk
SBC / Revenue4.4%C
Grade C: MedTTM stock-based comp / TTM Revenue
Quality
1/9 Loss Years84APiotroski F-Score7/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.50A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion206.3%A
Grade A: StrongFCF / Net Income
Margin Stability8.3%C
Grade C: AverageEBIT margin std deviation. Lower = stable
Capex / Revenue3.2%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.25xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
More metrics — Per Share, Balance Sheet, MarketHide additional metrics
Per Share
EPS (TTM)$0.91
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$13.63
Cash & short-term investments per share (Finnhub)
Book Value / Share$37.39
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$546.59M
Total debt obligations (short + long term)
Cash & Equiv.$784.53M
Cash and short-term investments
Net Debt$-237.95MA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$2.11B
Shareholders' equity (book value)
Asset / Liability3.55xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$10.70B
Current Market Capitalization
Beta1.13B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
Takeaway
Company is effectively debt-free after netting cash. · Current P/E of 209.1x is the highest in available history.
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Mar 2026 · Ratio snapshot Sep 26, 2026
Key Insights: Repligen Corp (RGEN)
Repligen Corp meets 7 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 8.54 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.50 suggests a low likelihood of earnings manipulation. Revenue has compounded at roughly 19% annually — a strong growth profile.
- Company is effectively debt-free after netting cash.
- Repligen Corp posted a net loss in 1 of 9 available completed fiscal years (2016–2025).
- At a valuation score of 10/100, RGEN trades at a premium to its historical multiples (P/E 209.1).
See how RGEN ranks on the Capex Tracker — top 50 capital spenders compared.
No significant market moves for RGEN in the last 30 days.
See RGEN move history →Frequently Asked Questions about RGEN
Is RGEN stock a buy right now?
PreMarketPrice's quantitative model rates Repligen Corp's financial health at 100/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is RGEN stock overvalued?
Repligen Corp trades at a trailing P/E of 209.1 and our valuation score rates it 10/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Repligen Corp report earnings?
No confirmed earnings date is currently scheduled for RGEN. The Earnings section lists recent reports and updates as dates are announced.
What sector does Repligen Corp operate in?
Repligen Corp operates in the Healthcare sector, within the Biological Products, (No Diagnostic Substances) industry. The Related Stocks section lists sector peers for comparison.
What does Repligen Corp do?
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies.
About Repligen Corp (RGEN) Stock
Repligen Corp (RGEN) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry. Real-time pricing data for Repligen Corp is available on this page with a market capitalization of $10.7 billion. The financial health score for RGEN is 100/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for RGEN stock.
RGEN Stock Analysis & Key Metrics
On PreMarketPrice, you can track Repligen Corp (RGEN) across multiple dimensions:
- Pre-market price & movement: Real-time RGEN stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for RGEN with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Repligen Corp across multiple reporting periods.
- Financial health score: A composite score of 100/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for RGEN.
- Sector peers: Compare RGEN against 10 other healthcare stocks on key financial metrics.
Is RGEN a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Repligen Corp (RGEN) as an investment. The financial health score of 100/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Repligen Corp (RGEN) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.